SK bioscience Co.,Ltd. (302440.KS)
KRW 54700.0
(-5.36%)
KRW 54700.0
(-5.36%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.73 Billion KRW | -137.84% |
| 2022 | 115.01 Billion KRW | -75.75% |
| 2021 | 474.21 Billion KRW | 1157.53% |
| 2020 | 37.71 Billion KRW | 65.42% |
| 2019 | 22.79 Billion KRW | 49.91% |
| 2018 | 15.2 Billion KRW | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -35.3 Billion KRW | -218.84% |
| 2024 Q2 | -28.07 Billion KRW | 20.48% |
| 2024 Q3 | -39.61 Billion KRW | -41.11% |
| 2023 Q2 | -35.3 Billion KRW | -20.97% |
| 2023 Q1 | -29.18 Billion KRW | -2040.13% |
| 2023 Q3 | 60.93 Billion KRW | 272.58% |
| 2023 Q4 | -11.07 Billion KRW | -118.17% |
| 2023 FY | -43.52 Billion KRW | -137.84% |
| 2022 FY | 115.01 Billion KRW | -75.75% |
| 2022 Q4 | 1.5 Billion KRW | -96.28% |
| 2022 Q3 | 40.49 Billion KRW | -33.83% |
| 2022 Q2 | 61.18 Billion KRW | 157.62% |
| 2022 Q1 | 23.75 Billion KRW | -90.65% |
| 2021 Q1 | 53.71 Billion KRW | 392.27% |
| 2021 FY | 474.21 Billion KRW | 1157.53% |
| 2021 Q4 | 253.94 Billion KRW | 152.92% |
| 2021 Q3 | 100.4 Billion KRW | 51.78% |
| 2021 Q2 | 66.15 Billion KRW | 23.16% |
| 2020 FY | 37.71 Billion KRW | 65.42% |
| 2020 Q2 | -3.09 Billion KRW | 29.98% |
| 2020 Q3 | 36.47 Billion KRW | 1280.14% |
| 2020 Q4 | 10.91 Billion KRW | -70.08% |
| 2020 Q1 | -4.41 Billion KRW | -188.18% |
| 2019 FY | 22.79 Billion KRW | 49.91% |
| 2019 Q4 | 5 Billion KRW | -44.18% |
| 2019 Q3 | 8.96 Billion KRW | -46.28% |
| 2019 Q2 | 16.69 Billion KRW | 312.11% |
| 2019 Q1 | -7.87 Billion KRW | -306.97% |
| 2018 Q4 | 3.8 Billion KRW | -66.65% |
| 2018 FY | 15.2 Billion KRW | 0.0% |
| 2018 Q3 | 11.4 Billion KRW | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 1.45 Billion KRW | 425.644% |
| Green Cross Holdings Corporation | -16.43 Billion KRW | 71.219% |
| Green Cross Holdings Corporation | 34.43 Billion KRW | 113.738% |
| Pharmicell Co., Ltd. | 950.99 Million KRW | 597.477% |
| Green Cross Corporation | 34.43 Billion KRW | 113.738% |
| GeneOne Life Science, Inc. | -48.36 Billion KRW | 90.219% |
| Celltrion, Inc. | 651.43 Billion KRW | 100.726% |
| Samsung Biologics Co.,Ltd. | 1155.98 Billion KRW | 100.409% |
| SK Biopharmaceuticals Co., Ltd. | -37.52 Billion KRW | 87.391% |
| Prestige BioPharma Limited | -62.78 Billion KRW | 92.465% |